Publications

Zhang et al. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.

Science Advances, 2017. May 17;3(5):e1602133. PMID 28560327

Wu JD. Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.

OncoImmunology. 2016;5(3):e1095434 

Lu S, Zhang J, Liu D, Li G, Staveley-O'Carroll KF, Li Z, and Wu. Nonblocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive anti-tumor responses and eliminates primary and metastatic tumors.

Clin Cancer Res. 2015;21:4819-4830.

Zhang J, Basher F, and Wu JD. NKG2D Ligands in Tumor Immunity: Two Sides of a Coin.

Front Immunol. 2015;6:97. (Review)

Xiao G, Wang X, Sheng J, Lu S, Yu X, and Wu JD. Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype.

J Hematol Oncol. 2015;8(1):13.

Liu G, Lu S, Wang X, et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.

J Clin Invest. 2013;123(10):4410-22.

Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, and Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.

J Clin Invest. 2004;114(4):560-568.

Groh V, Wu J, Yee C, and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.

Nature. 2002;419(6908):734-738.

Dhar P and Wu JD.

NKG2D and its ligands in cancer.

Curr Opin Immunol. 2018 Mar 8;51:55-61